Deborah Hung, M.D., Ph.D.


Physician Investigator (NonCl)
Molecular Biology, Mass General Research Institute
Associate Professor of Medicine
Harvard Medical School
Professor of Genetics
Harvard Medical School
Consultant
Infectious Disease, Massachusetts General Hospital
Research Staff
Molecular Biology, Massachusetts General Hospital
MD Harvard Medical School 1997
MD Harvard Medical School/ BWH 1997
PhD Harvard University 1997
anti-bacterial agents; antitubercular agents; bacteria; bacterial proteins; bacterial toxins; bile acids and salts; biofilms; bioterrorism; gene expression regulation bacterial; host-pathogen interactions; mycobacterium tuberculosis; pseudomonas aeruginosa; vibrio cholerae; virulence

We are facing an incredible challenge in the realm of infectious diseases that has been brought on by the convergence of three current phenomenanewly emerging infectious organisms, a global crisis in antibiotic resistance, and the threat of bioterrorism.  A response to this challenge requires a renewed devotion to understanding the underlying mechanisms involved in infection and an increased commitment to the discovery of new antibiotics.

The goal of research in the Hung Lab is to understand in vivo mechanisms of bacterial pathogenesis by studying pathogen-host interactions. By merging the fields of chemical genetics and bacterial genetics/genomics, we hope to provide insight into possible new paradigms for addressing infectious diseases.

Despite recent, largely genetic, technical advances in the field of in vivo pathogen-host interactions, many important questions related to the mechanisms of bacterial pathogenesis remain unanswered, in part because of the inability of in vitro conditions to accurately mimic in vivo ones. The newly developing field of chemical genetics offers a novel and promising approach to studying these mechanisms, thus complementing traditional genetic studies. Chemical genetics uses small organic molecules as specific tools to conditionally induce a phenotype by activating or inhibiting specific protein targets, thus allowing the manipulation of relevant pathways in vitro and in vivo, on very short time scales.

In concert with taking a chemical biological approach to pathogenesis, our lab is interested in developing powerful genomic approaches to systematically and comprehensively identify all bacterial genes required for infection and to facilitate rapid identification of small molecule targeted pathways and interactions. Using small molecules that we identify and develop from high-throughput, forward phenotypic screens and arrayed, knockout libraries of different pathogens, including Vibrio cholerae, Pseudomonas aeruginosa and Mycobacterium tuberculosis, we hope to identify new approaches to disease intervention.